Revenue
2018
2019
2020
2021
2022
2023
2024
2025
XBiotech Inc. (XBIT)
Price$2.20Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $4.0M | $18.4M | $44.0M | $0 | $0 | — | — | — | — | — |
| Gross profit | — | — | $0 | $3.4M | $12.6M | $9.4M | $0 | $0 | — | — | — | — | — |
| Gross margin | — | — | — | 83.77% | 68.36% | 21.48% | — | — | — | — | — | — | — |
| Research & development | $47.4M | $37.8M | $32.8M | $31.5M | $28.3M | $9.5M | $24.1M | $15.7M | $26.4M | $42.5M | $31.3M | $14.3M | $7.9M |
| Operating expenses | $55.7M | $42.5M | $37.5M | $37.8M | $37.7M | $27.7M | $31.2M | $21.0M | $34.1M | $52.8M | $37.5M | $21.8M | $9.9M |
| Operating income | −$55.7M | −$42.5M | −$37.5M | −$34.5M | −$25.1M | −$18.3M | −$31.2M | −$21.0M | −$34.1M | −$52.8M | −$37.5M | −$21.8M | −$9.9M |
| Operating margin | — | — | — | −860.10% | −136.36% | −41.54% | — | — | — | — | — | — | — |
| EBITDA | −$54.0M | −$40.7M | −$35.8M | −$31.9M | −$22.4M | −$16.0M | −$28.9M | −$18.6M | −$32.6M | −$52.1M | −$36.8M | −$21.1M | −$9.1M |
| EBITDA margin | — | — | — | −794.91% | −121.96% | −36.45% | — | — | — | — | — | — | — |
| Net income | −$45.5M | −$38.5M | −$24.6M | −$32.9M | −$17.4M | −$11.2M | $668.6M | −$21.1M | −$33.1M | −$52.8M | −$37.5M | −$21.7M | −$9.9M |
| Net profit margin | — | — | — | −820.45% | −94.67% | −25.50% | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$1.49 | -$1.26 | -$0.81 | -$1.08 | -$0.58 | -$0.36 | $17.17 | -$0.59 | -$0.95 | -$1.63 | -$1.22 | -$0.90 | -$0.45 |
| Diluted EPSper diluted share | -$1.49 | -$1.26 | -$0.81 | -$1.08 | -$0.58 | -$0.36 | $14.44 | -$0.59 | -$0.95 | -$1.63 | -$1.22 | -$0.90 | -$0.45 |
Owners
Reported shareholders
1.05%of listed shares
BlackRock, Inc.321.15K shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 1.05%321.15K shares |
Kuendig Thomas Martin | ≈0.98%300K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.70%214.12K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.66%200.18K shares |
RBF Capital, LLC | 0.65%198.5K shares |
Rademaker Craig Evan | ≈0.56%170.99K shares |
MORGAN STANLEY | 0.49%147.88K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.32%98.45K shares |
VANGUARD FIDUCIARY TRUST CO | 0.30%92.37K shares |
MILLENNIUM MANAGEMENT LLC | 0.26%79.33K shares |
STATE STREET CORP | 0.24%73.01K shares |
NORTHERN TRUST CORP | 0.22%66.26K shares |
Empowered Funds, LLC | 0.20%59.55K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.14%41.66K shares |
Bank of New York Mellon Corp | 0.13%39.36K shares |
DIMENSIONAL FUND ADVISORS LP | 0.12%36.05K shares |
Squarepoint Ops LLC | 0.11%34.76K shares |
Qube Research & Technologies Ltd | 0.11%33.57K shares |
GSA CAPITAL PARTNERS LLP | 0.10%30.65K shares |
CITADEL ADVISORS LLC | 0.10%29.19K shares |
Percentages use 30.49M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data